A Phase III Multi-centre, Open-label, follow-on Study to CDP870-027, to Assess the Efficacy and Safety of Lyophilized CDP870 an Engineered Human Anti-TNF PEG Conjugate, as Additional Medication to Methotrexate, in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Certolizumab pegol (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Registrational
- Acronyms RAPID-1
- Sponsors UCB
- 06 Jun 2020 Results pooled analysis of efficacy from 4 trials (RAPID 1, RAPID 2, J-RAPID and RAPID-C), presented at the 21st Annual Congress of the European League Against Rheumatism
- 06 Nov 2013 Workplace and household productivity results presented at the 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research.
- 30 Oct 2013 Results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.